HOPLive24-MPN

Ruben Mesa, MDUncategorized | June 7, 2024
In the last segment of the roundtable series, the panel discusses the future of myelofibrosis treatment.
Ruben Mesa, MDUncategorized | July 2, 2024
The panel discusses the four JAK inhibitors approved by the FDA: ruxolitinib, fedratinib, pacritinib, and momelotinib.
Ruben Mesa, MDThe HemOnc Pulse Live | June 7, 2024
In the sixth segment of the roundtable series, the panel discusses momelotinib and pacritinib treatment in myelofibrosis.
Advertisement
Ruben Mesa, MDThe HemOnc Pulse Live | June 7, 2024
The panel discusses fedratinib for myelofibrosis and whether it's used in the frontline or second line setting.
Ruben Mesa, MDThe HemOnc Pulse Live | June 7, 2024
In the fourth segment of the roundtable series, the panel discusses frontline ruxolitinib treatment for myelofibrosis.
Ruben Mesa, MDThe HemOnc Pulse Live | June 7, 2024
This roundtable session addresses which patients go directly to transplant, when to observe patients, and more.
Advertisement
Ruben Mesa, MDVideo Insights | June 7, 2024
In the first segment of the roundtable series, the panel discusses how myelofibrosis is diagnosed and assessed.
Ruben Mesa, MDVideo Insights | June 7, 2024
Dr. Naveen Pemmaraju discusses the history of prognostic scoring systems and how they factor into frontline therapy planning.
Advertisement
Advertisement
Editorial Board